ATE317260T1 - Pharmazeutische formulierungen mit platinderivaten - Google Patents

Pharmazeutische formulierungen mit platinderivaten

Info

Publication number
ATE317260T1
ATE317260T1 AT02787779T AT02787779T ATE317260T1 AT E317260 T1 ATE317260 T1 AT E317260T1 AT 02787779 T AT02787779 T AT 02787779T AT 02787779 T AT02787779 T AT 02787779T AT E317260 T1 ATE317260 T1 AT E317260T1
Authority
AT
Austria
Prior art keywords
pharmaceutical formulations
formulations containing
containing platinum
platinum derivatives
derivatives
Prior art date
Application number
AT02787779T
Other languages
English (en)
Inventor
Sara Lauria
Alessandro Martini
Cristina Ciocca
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21744006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE317260(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Application granted granted Critical
Publication of ATE317260T1 publication Critical patent/ATE317260T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT02787779T 2001-12-06 2002-11-22 Pharmazeutische formulierungen mit platinderivaten ATE317260T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/010,122 US6476068B1 (en) 2001-12-06 2001-12-06 Platinum derivative pharmaceutical formulations

Publications (1)

Publication Number Publication Date
ATE317260T1 true ATE317260T1 (de) 2006-02-15

Family

ID=21744006

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02787779T ATE317260T1 (de) 2001-12-06 2002-11-22 Pharmazeutische formulierungen mit platinderivaten

Country Status (41)

Country Link
US (3) US6476068B1 (de)
EP (1) EP1453517B1 (de)
JP (1) JP2005515202A (de)
KR (1) KR100941210B1 (de)
CN (1) CN100540006C (de)
AP (1) AP1760A (de)
AR (1) AR037629A1 (de)
AT (1) ATE317260T1 (de)
AU (1) AU2002352105B2 (de)
BR (1) BR0214757A (de)
CA (1) CA2468916C (de)
CO (1) CO5580776A2 (de)
CR (1) CR7362A (de)
CY (1) CY1105608T1 (de)
DE (1) DE60209145T2 (de)
DK (1) DK1453517T3 (de)
EA (1) EA008090B1 (de)
EC (1) ECSP045140A (de)
ES (1) ES2258661T3 (de)
GE (1) GEP20063895B (de)
HR (1) HRP20040514A2 (de)
HU (1) HUP0402217A3 (de)
IL (2) IL162348A0 (de)
IS (1) IS2580B (de)
MA (1) MA27153A1 (de)
ME (1) MEP10408A (de)
MX (1) MXPA04005423A (de)
MY (1) MY134422A (de)
NO (1) NO330159B1 (de)
NZ (1) NZ533383A (de)
OA (1) OA12739A (de)
PL (1) PL206755B1 (de)
PT (1) PT1453517E (de)
RO (1) RO121509B1 (de)
RS (1) RS50360B (de)
SI (1) SI21493A (de)
TN (1) TNSN04104A1 (de)
TW (1) TW200409640A (de)
UA (1) UA77728C2 (de)
WO (1) WO2003047587A1 (de)
ZA (1) ZA200404525B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1404689A1 (de) * 2001-07-02 2004-04-07 Debiopharm S.A. Aktive oxiplatinverbindung mit sehr niedrigem oxalsaüregehalt
CA2388352A1 (en) * 2002-05-31 2003-11-30 Voiceage Corporation A method and device for frequency-selective pitch enhancement of synthesized speed
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
DE10314377A1 (de) * 2003-03-28 2004-10-07 Stada Arzneimittel Ag Gebrauchsfertige Oxaliplatin-Lösungen
CA2537170A1 (en) * 2003-08-28 2005-03-10 Mayne Pharma Pty Ltd Acid containing oxaliplatin formulations
GB2441445B (en) * 2003-08-28 2008-04-23 Mayne Pharma Ltd Acid containing oxaliplatin formulation
JP4823914B2 (ja) * 2003-11-07 2011-11-24 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｆｇｆｒ３の阻害および多発性骨髄腫の治療
RU2273475C2 (ru) * 2004-04-06 2006-04-10 Государственное учреждение системы высшего и послевузовского профессионального образования "Сибирский государственный медицинский университет" (ГУ СВ ПО СибГМУ) Способ лечения диссеминированного колоректального рака
US7795205B2 (en) * 2004-04-12 2010-09-14 Canyon Pharmaceuticals, Inc. Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor
NZ551637A (en) * 2004-06-09 2010-05-28 Taiho Pharmaceutical Co Ltd Antitumor effect fortifier, antitumor agent and method of therapy for cancer
JP2007505165A (ja) * 2004-07-12 2007-03-08 シコール インコーポレイティド シス−ジヨード−（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ｉｉ）錯体及び高純度オキサリプラチンの調製方法
US20060063833A1 (en) * 2004-09-22 2006-03-23 Edgar Schridde Ready-to-use oxaliplatin solutions
US20060063720A1 (en) * 2004-09-22 2006-03-23 Edgar Schridde Oxaliplatin solution concentrate
DE102004052877B4 (de) * 2004-11-02 2008-06-19 Ebewe Pharma Ges.M.B.H. Nfg.Kg Stabile wässrige Formulierungen eines Platin-Derivats
CN1311818C (zh) * 2004-11-22 2007-04-25 山东蓝金生物工程有限公司 一种抗实体肿瘤的药物组合物
DE102004063764A1 (de) * 2004-12-29 2006-07-13 Hexal Ag Kunststoff-Flasche für Oxaliplatin
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
EP1879568B1 (de) * 2005-03-28 2009-05-06 Dabur Pharma Limited Stabile pharmazeutische zusammensetzungen aus antitumoralen platin-(ii)-mitteln
AU2006247803B2 (en) * 2005-05-13 2011-12-22 Novartis Ag Methods for treating drug resistant cancer
DE102005038347A1 (de) * 2005-08-11 2007-02-15 Hexal Ag Herstellung einer Oxaliplatin-Lösung und Behälter sowie Behälter-Set mit der Lösung
WO2007029268A2 (en) * 2005-09-05 2007-03-15 Dabur Pharma Limited Stable oxaliplatin formulation
KR20080074143A (ko) * 2005-11-29 2008-08-12 노파르티스 아게 퀴놀리논 제제
US20090076139A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched oxalplatin
US20100267824A1 (en) * 2007-11-12 2010-10-21 Intas Pharmaceuticals Limited Stable oxaliplatin composition for parenteral administration
CN101969926A (zh) * 2008-02-29 2011-02-09 赛多仕有限公司 拓扑替康即用溶液
WO2010056847A2 (en) * 2008-11-13 2010-05-20 Taigen Biotechnology Co., Ltd. Lyophilization formulation
MX348668B (es) 2009-09-21 2017-06-23 J W Pharmaceutical Corp * Nanopartículas de oxaliplatin y método para prepararlas.
US9387152B2 (en) 2010-06-28 2016-07-12 The General Hospital Corporation Blood substitutes and uses thereof
CN102274171A (zh) * 2011-08-04 2011-12-14 上海希迪制药有限公司 一种奥沙利铂注射剂
WO2014015027A1 (en) 2012-07-18 2014-01-23 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
JP5929607B2 (ja) * 2012-08-06 2016-06-08 ニプロ株式会社 オキサリプラチン製剤
CN102885765B (zh) * 2012-10-25 2013-11-06 哈药集团生物工程有限公司 一种盐酸伊立替康注射液及其制备方法
US10098813B2 (en) 2014-09-03 2018-10-16 Sun Pharmaceutical Industries Limited Perfusion dosage form
KR101683635B1 (ko) * 2014-12-29 2016-12-09 가천대학교 산학협력단 락테이트 금속염을 포함하는 암 치료용 약학 조성물
EP4011377B1 (de) * 2015-02-13 2024-10-23 Sun Pharmaceutical Industries Ltd Darreichungsform für intravenöse infusion enthaltend pemetrexed
KR102293907B1 (ko) 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
CN109069342A (zh) 2016-02-09 2018-12-21 太阳医药工业有限公司 灌注系统
CN109996809A (zh) 2016-11-14 2019-07-09 诺华股份有限公司 与促融合蛋白minion相关的组合物、方法和治疗用途
KR20250042852A (ko) 2018-01-12 2025-03-27 (주) 메티메디제약 만성 염증성 질환의 치료 방법
KR101998246B1 (ko) 2018-08-22 2019-07-10 주식회사 메타파인즈 금속이온에 결합된 이온화합물을 포함하는 암 치료용 약학 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US5041578A (en) * 1988-11-22 1991-08-20 Board Of Regents, The University Of Texas System Water soluble 1,2-diaminocyclohexane platinum (IV) complexes as antitumor agents
ZA928771B (en) 1991-11-15 1993-09-08 Smithkline Beecham Corp Combination chemotherapy
JPH0776230B2 (ja) 1992-01-13 1995-08-16 田中貴金属工業株式会社 白金化合物の製造方法
JP2673331B2 (ja) 1993-01-12 1997-11-05 田中貴金属工業 株式会社 光学的に高純度なシス―オキザラート（トランス―１―１，２―シクロヘキサンジアミン）白金（▲ｉｉ▼）
JPH06287021A (ja) 1992-04-22 1994-10-11 Tanaka Kikinzoku Kogyo Kk 光学活性な白金錯化合物の光学的分割方法
AU5416394A (en) 1992-11-24 1994-06-22 Debiopharm S.A. Cisplatinum/oxaliplatinum combination
CA2149150C (en) * 1992-11-27 2000-08-01 David R. Carver Injectable taxol composition with improved stability
JP3025602B2 (ja) 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
US5455270A (en) * 1993-08-11 1995-10-03 Bristol-Myers Squibb Co. Stabilized solutions of platinum(II) antitumor agents
AU2989695A (en) 1994-08-08 2000-03-07 Debiopharm S.A. Pharmaceutically stable oxaliplatinum preparation
EP0715854B1 (de) 1994-11-11 2003-09-10 Debiopharm S.A. Karzinostatische Zusammensetzungen, welche Cis-Oxaliplatin und eine oder mehrere andere verträgliche Karzinostatika enthalten
US5919816A (en) 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
WO1996026949A1 (en) * 1995-02-28 1996-09-06 Debiopharm Sa Novel platinum (iv) complexes, process for producing the same, and carcinostatic agents containing the same
US5776959A (en) 1995-06-05 1998-07-07 Washington University Anticonvulsant and anxiolytic lactam and thiolactam derivatives
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス．アー． 白金化合物の製造方法
AU2163797A (en) * 1996-03-11 1997-10-01 Debiopharm S.A. Binuclear platinum complexes, method for preparing same and pharmaceutical compositions containing said complexes
ATE252372T1 (de) 1996-08-23 2003-11-15 Sequus Pharm Inc Liposome enthaltend cisplatin
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
EA002630B1 (ru) 1997-02-05 2002-08-29 Фармация Энд Апджон Компани Способ получения липидных комплексов или липосом водонерастворимого диаминоциклогександикарбоксилата платины
EP1014990B1 (de) 1997-03-07 2006-09-06 Sanofi-Aventis U.S. LLC Antitumorkombination aus 3-amino-1,2,4-benzotriazine 1,4-dioxid/paclitaxel/platin
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
GB9804013D0 (en) * 1998-02-25 1998-04-22 Sanofi Sa Formulations
DE69901725T2 (de) 1998-10-14 2003-01-30 Debiopharm S.A., Lausanne Verpackung eines oxaliplatinhaltigen arzneimittels
CA2382389C (fr) 1999-08-30 2010-06-29 Debiopharm S.A. Preparation pharmaceutique stable d'oxaliplatine pour administration par voie parenterale
AU2001240001A1 (en) 2000-03-08 2001-09-17 Bristol-Myers Squibb Company Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same
SE0003026D0 (sv) * 2000-08-25 2000-08-25 Kerstin Sunnerheim Use for conifer sapling protection

Also Published As

Publication number Publication date
IL162348A (en) 2010-11-30
PL370254A1 (en) 2005-05-16
YU59704A (sh) 2006-08-17
HUP0402217A2 (hu) 2005-01-28
TW200409640A (en) 2004-06-16
AU2002352105A1 (en) 2003-06-17
CA2468916A1 (en) 2003-06-12
KR100941210B1 (ko) 2010-02-10
AR037629A1 (es) 2004-11-17
MXPA04005423A (es) 2004-10-11
HK1072002A1 (zh) 2005-08-12
AU2002352105B2 (en) 2009-12-03
UA77728C2 (en) 2007-01-15
US20030109514A1 (en) 2003-06-12
AP2004003055A0 (en) 2004-06-30
EP1453517A1 (de) 2004-09-08
ECSP045140A (es) 2004-08-27
NZ533383A (en) 2007-02-23
EA008090B1 (ru) 2007-02-27
SI21493A (sl) 2004-12-31
JP2005515202A (ja) 2005-05-26
RO121509B1 (ro) 2007-10-30
NO330159B1 (no) 2011-02-28
DE60209145D1 (de) 2006-04-20
ES2258661T3 (es) 2006-09-01
PT1453517E (pt) 2006-06-30
CR7362A (es) 2009-02-12
CN100540006C (zh) 2009-09-16
RS50360B (sr) 2009-11-10
MA27153A1 (fr) 2005-01-03
ZA200404525B (en) 2005-08-15
DE60209145T2 (de) 2006-10-26
IL162348A0 (en) 2005-11-20
GEP20063895B (en) 2006-08-10
CO5580776A2 (es) 2005-11-30
CN1612737A (zh) 2005-05-04
US20030109515A1 (en) 2003-06-12
DK1453517T3 (da) 2006-06-19
MEP10408A (en) 2011-02-10
US6673805B2 (en) 2004-01-06
US6476068B1 (en) 2002-11-05
EP1453517B1 (de) 2006-02-08
HUP0402217A3 (en) 2005-11-28
HRP20040514A2 (en) 2004-10-31
IS7298A (is) 2004-06-03
TNSN04104A1 (fr) 2006-06-01
EA200400777A1 (ru) 2004-12-30
CY1105608T1 (el) 2010-12-22
KR20050058278A (ko) 2005-06-16
NO20042842L (no) 2004-07-05
WO2003047587A1 (en) 2003-06-12
AP1760A (en) 2007-07-18
BR0214757A (pt) 2004-09-14
IS2580B (is) 2010-02-15
MY134422A (en) 2007-12-31
CA2468916C (en) 2009-01-20
PL206755B1 (pl) 2010-09-30
OA12739A (en) 2006-06-30

Similar Documents

Publication Publication Date Title
ATE307571T1 (de) Pharmazeutische formulierung enthaltend bicalutamid
IS2580B (is) Platínuafleiða lyfjasamsetningar
ATE320244T1 (de) Pharmazeutische zusammensetzungen mit amlodipinmaleat
ITTO20010008A0 (it) Formulazione farmaceutica
NO20033384D0 (no) Farmasöytisk formulering
ATE334656T1 (de) Flüssige pharmazeutische zusammensetzung
NO20033556L (no) Farmasöytiske formuleringer
DE60142197D1 (de) Pharmazeutische Zusammensetzung
ATE331529T1 (de) Antigen enthaltende pharmazeutische zusammensetzung
DE60111769D1 (de) Flüssige pharmazeutische formulierungen mit verbesserter oraler veträglichkeit
DE602004016967D1 (de) Flüssige pharmazeutische palonosetronformulierungen
ATE320807T1 (de) Pharmazeutische zusammensetzungen enthaltend tegaserod
NO20035627D0 (no) Farmasöytisk formulering
ATE324883T1 (de) Pharmazeutische zusammensetzung enthaltend lumiracoxib
ATE477814T1 (de) Stabile faktor-viii enthaltende pharmazeutische zusammensetzung
ATE350016T1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
ATE366128T1 (de) Pharmazeutische zusammensetzung
ATE507831T1 (de) Melatonin enthaltende pharmazeutische formulierung
NO20041485L (no) Farmasoytisk formulering omfattende (R)-bicalutamid
DE10291905D2 (de) Pharmazeutische Zusammensetzung
ATE350029T1 (de) Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
DE10107261B4 (de) Pharmazeutische Zusammensetzung
NO20041236L (no) Farmasoytisk formulering
SE0102572D0 (sv) Pharmaceutical formulation
SE0101326D0 (sv) Pharmaceutical formulation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1453517

Country of ref document: EP

EEIH Change in the person of patent owner